MiNK Therapeutics, Inc.
INKT Nasdaq
SEC CIK 1840229
Follow MiNK Therapeutics
Weekly email: filings, results
Revenue, last quarter
$200K
Net income
−$2.6M
+11.6% vs same quarter last year
EPS, diluted
−$0.50
+23.1% vs same quarter last year
Operating cash flow
−$1.3M
−35.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$12.5M |
| FY24 | −$10.8M |
| FY23 | −$22.5M |
| FY22 | −$28M |
| FY21 | −$30.2M |
| FY20 | −$16.2M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$15.8M |
| FY22 | −$19.1M |
| FY21 | −$13.1M |
| FY20 | −$8.4M |
| FY19 | - |